New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

KARDIGAN INC

KARD

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

11.54 0.98 −7.83%

After hours trading: 11.54, unchanged, last trade Fri 4:01pm Eastern.

Market cap
$1.2B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−187.2%
Net debt / EBITDA
1.7×
Payout ratio
—

KARDIGAN INC (KARD) SEC filings, changes and red flags

Red flags

No red flags have been raised by KARDIGAN INC’s filings on file.

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026
8-K Nov 12, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Nov 6, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Sep 29, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026
8-K Aug 11, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jun 22, 2026 5.03 Amendments to the articles or bylaws; change in fiscal year; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.